Ying Han

An ider(17)(q10)t(15;17) with spliced long-type PML-RARA fusion transcripts in a case of acute promyelocytic leukemia.

Jumei Shi, Y. Tao, J. Hou, 2014, Cancer genetics.

Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials.

F. Zhan, Jumei Shi, Guang Yang, 2015, International journal of clinical and experimental medicine.

Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I.

F. Zhan, Jumei Shi, Junhua Zheng, 2011, Biochemical and biophysical research communications.

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.

F. Zhan, Hongwei Xu, Lu Gao, 2014, Acta biochimica et biophysica Sinica.

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2

F. Zhan, G. Tricot, M. Zangari, 2010, Cancer biology & therapy.

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

F. Zhan, Hongwei Xu, Lu Gao, 2015, Oncotarget.

Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

F. Zhan, Hongwei Xu, Lu Gao, 2014, Acta biochimica et biophysica Sinica.

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma

Gege Chen, Liangning Hu, Bingqian Xie, 2016, Oncotarget.

Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials

F. Zhan, Hongwei Xu, Lu Gao, 2014, PloS one.